
PuREC
Founded Year
2016Stage
Series B | AliveTotal Raised
$11.78MLast Raised
$5.71M | 2 yrs agoAbout PuREC
PuREC conducts R&D for therapeutic REC (Rapidly Expanding Cells) preparations and markets REC as research reagents. The company aims to establish practical applications of regenerative medicine technologies using bone marrow-derived mesenchymal stem cells (BM-MSCs).
Loading...
Loading...
PuREC Patents
PuREC has filed 3 patents.
The 3 most popular patent topics include:
- biotechnology
- developmental biology
- stem cells

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
3/2/2021 | 9/13/2022 | Transcription factors, Monoclonal antibodies, Stem cells, Biotechnology, Developmental biology | Grant |
Application Date | 3/2/2021 |
---|---|
Grant Date | 9/13/2022 |
Title | |
Related Topics | Transcription factors, Monoclonal antibodies, Stem cells, Biotechnology, Developmental biology |
Status | Grant |
Latest PuREC News
Jul 11, 2021
. A NEW ORLEANS, La., July 11, 2021 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until July 12, 2021 to file lead plaintiff applications in securities class action lawsuits against PureCycle Technologies, Inc. (NasdaqCM: PCT) f/k/a Roth CH Acquisition I Co. ("Roth") (Nasdaq: ROCH), if they purchased PureCycle and/or Roth securities between November 16, 2020 and May 5, 2021, inclusive (the "Class Period") and/or were holders of Roth securities entitled to participate in the March 16, 2021 shareholder vote on the merger with PureCycle. These actions are pending in the United States District Court for the Middle District of Florida. What You May Do If you purchased and/or held securities of PureCycle and/or Roth as above and would like to discuss your legal rights and how these cases might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( lewis.kahn@ksfcounsel.com ), or visit https://www.ksfcounsel.com/cases/nasdaqcm-pct/ to learn more. If you wish to serve as a lead plaintiff in the class actions, you must petition the Courts by July 12, 2021. About the Lawsuits PureCycle and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. Specifically, the action alleges that the Company failed to disclose that increases in commodity and freight costs had been negatively impacting the Company's business and operations. On May 6, 2021, pre-market, Hindenburg Research reported a wide range of criticisms toward the Company related to its prior "going public" transaction with Roth and present position, concluding that the Company "represents the worst qualities of the SPAC boom; another quintessential example of how executives and SPAC sponsors enrich themselves while hoisting unproven technology and ridiculous financial projections onto the public markets, leaving retail investors to face the ultimate consequences." On this news, shares of PureCycle plummeted more than 40%, or approximately $10 per share, on very unusually high trading volume. The first-filed case is Theodore v. PureCycle Technologies, Inc., et al., No. 21-cv-809. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana. To learn more about KSF, you may visit www.ksfcounsel.com . Contact:
PuREC Frequently Asked Questions (FAQ)
When was PuREC founded?
PuREC was founded in 2016.
Where is PuREC's headquarters?
PuREC's headquarters is located at Shimane Shimane University School of Medicine, Izumo.
What is PuREC's latest funding round?
PuREC's latest funding round is Series B.
How much did PuREC raise?
PuREC raised a total of $11.78M.
Who are the investors of PuREC?
Investors of PuREC include Gogin Capital, San-in Godo Bank, Mochida Pharmaceutical, Hiromitsu Nakauchi, Fast Track Initiative and 5 more.
Loading...
Loading...